This is because the Central Pharmaceutical Affairs Review Committee, a specialized advisory body for the MFDS, determines the adequacy of the approval from 2pm.

While it is expected that the Central Pharmaceutical Affairs Review Committee has decided on item approval, it is noteworthy how it will decide on the administration of the elderly. Earlier, the 1st expert meeting, Verification Advisory Group, suggested the use of the vaccine, saying, "There is no reason to exclude the administration of AstraZeneca’s vaccine to the elderly."

The MFDS will hold an advisory meeting on the Central Pharmaceutical Affairs Review Committee for AZ Vaccine in a conference room at the headquarters